Search results
Results from the WOW.Com Content Network
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy, [6] [7] and only the second malaria vaccine to be recommended by the WHO. [8] In April 2023, Ghana's Food and Drugs Authority approved the use of the R21 vaccine for use in children aged between five months and three ...
Two types of dengue vaccine have been approved and are commercially available. Dengvaxia became available in 2016, but it is only recommended to prevent re-infection in individuals who have been previously infected. [13] The second vaccine, Qdenga, became available in 2022 and is suitable for adults, adolescents and children from four years of ...
The WHO-prequalified vaccine, called TAK-003, is recommended for children 6–16 years old who are in environments where dengue spread is high and burdensome on public health.
RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's ...
New data from a phase 3 trial of R21/Matrix-M in African children confirmed the jab is effective and safe. Malaria vaccine is highly effective in young children, study suggests Skip to main content
The List of Prequalified Vaccines, published by the World Health Organization, lists vaccines that are found to be safe, effective and of good quality, after undergoing investigation of relevant data, testing and examination of their production sites. [1] [2] [3] [4]
A new vaccine candidate was more than 83 percent effective at protecting against hospitalizations over a three-year clinical trial. Dengue virus is a mosquito-borne disease that can cause severe ...